Open Site Navigation
Liita_logo_green_dark.png

We’re LIIRA CARE

Redefining respiratory self-care

Liita_logo_green_dark.png

Redefining respiratory self-care

LIITA Care is a late-stage biotech company dedicated to the discovery and development of novel therapies that improve the lives of consumers suffering from respiratory diseases

Our mission is to become a global provider of the future go-to solution for respiratory self-care. We do this by transforming the cough and cold category with our portfolio of clinically documented over-the-counter treatments

Our patented technology deploys NaCl microparticles in a new and consumer-friendly treatment form proven to be clinically beneficial in diseases that affect more than 80% of the world's population

Liita_logo_green.png

Our Product Pipeline

Diversified and innovative pipeline including late-stage assets open the opportunity for position as global go-to brand for NaCl particle inhalation

Liita_logo_green.png

Research

We are the first company in the world to introduce salt particle inhalation to the market.Thanks to our cutting edge research we are the company with the most extensive knowledge within inhaled salt therapy and respiratory disease.

We have scientific collaborations with the leading universities in the field.

Our research is supported by Innovation Fund Denmark. In 2020 we received a prestigious grand, Grand Solutions from Innovation Fund Denmark for scientific research in Covid-19.

We have been selected as the best in class in ERS Congress 2022 to present our latest, ground-breaking scientific discoveries regarding COVID-19 treatment.

Latest News

Catch up on the latest news & updates here

05 September 2022 • Press Release

LIITA Research to be Presented at the ERS Congress 2022

We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
 
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
 
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
 

 

02 September 2022 • Media Update

LIITA Research to be Presented at ERS Congress 2022

We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona. 

 

“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form” 

 

“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil). 

 

Come join us Monday the 5th of September at 12.45 pm (Room 8L).

2022 • News Article

Stay tuned for more news

TBA

Browse All News

Board member

Henrik Kjær Hansen

Novo Holdings

  • LinkedIn

Board member

Jakob Ottesen Thiesson

Boston Consulting Group

  • LinkedIn

Board member

Martin Røssberg

MR Law

  • LinkedIn

CEO & Founder

Martin Ohrt

LIITA Care

  • LinkedIn

CFO

Søren Kjær Henningsen

LIITA Care

  • LinkedIn
Board of Directors
Management

Latest News

Catch up on the latest news & updates here

Latest News

Catch up on the latest news & updates here